Work

Computational Probing of CNP520: A Clinical Trial Drug Candidate for BACE1 of Alzheimer's Disease

Year: 2020
Type: preprint
Abstract: Alzheimer disease (AD) is a neurodegenerative disorder which leads to dementia. Among several hypotheses Amyloid cascade hypothesis is believed to play a major role in AD. The amyloid cascade hypothesis states that AD is caused due to the formation of peptide known as amyloid beta (Aβ40 and Aβ42). These amyloid beta aggregates to form extracellular plaques and neurofibrillary tangles. This causes neuronal and synaptic dysfunction which affects the cognitive function of the brain. This amyloid beta is produced by the Beta-site amyloid precursor protein cleaving enzyme1 (BACE1 or β-secretase) while processing amyloid precursor protein (APP) along with γ-secretase. Thus, inhibition of BACE1 will lowers the production of Aβ. Inhibition of β-secretase is preferred over γ-secretase since β-secretase is present only in amyloidogenic pathway whereas γ-secretase is present in both amyloidogenic and non-amyloidogenic pathway. Umibecestat (CNP520) from Amgen, Inc., Novartis Pharmaceuticals Corporation, a clinical trial drug candidate for BACE1 of Alzheimer’s Disease which passed the Phase II of clinical trial but failed in Phase III[4]. To understand the reasons for the failure of CNP520 in clinical trial, we have undertaken in silico Molecular Docking, Molecular Dynamic simulation, QSAR and ADME calculations using Schrodinger software package. Our results suggest that subtle interactions at the molecular level between the CNP520 and BACE1 might modulate the binding affinity of the complex and the inhibition efficiency of the BACE1. This present investigation through light on the possible reasons of the clinical failure of CNP520 as a drug to Alzheimer’s Disease and pave the way to design the right one.
Language: English
Open Access status: green
OpenAlex ID: W3173651352
Cites:
Cited by:
Related to: 10